243 related articles for article (PubMed ID: 36601798)
1. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
Varnado OJ; Ye W; Mi X; Burge R; Hall J
J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
[TBL] [Abstract][Full Text] [Related]
2. Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials.
Tobin J; Ford JH; Tockhorn-Heidenreich A; Nichols RM; Ye W; Bhandari R; Mi X; Sharma K; Lipton RB
J Med Econ; 2022; 25(1):630-639. PubMed ID: 35510376
[TBL] [Abstract][Full Text] [Related]
3. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
4. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
5. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
Ford JH; Stauffer VL; McAllister P; Akkala S; Sexson M; Ayer DW; Wang S
Qual Life Res; 2021 Feb; 30(2):455-464. PubMed ID: 32944843
[TBL] [Abstract][Full Text] [Related]
6. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
[TBL] [Abstract][Full Text] [Related]
7. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
Tepper SJ; Dong Y; Vincent M; Wietecha LA
Headache; 2023; 63(10):1380-1390. PubMed ID: 37132481
[TBL] [Abstract][Full Text] [Related]
8. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
Ford JH; Ayer DW; Zhang Q; Carter JN; Leroux E; Skljarevski V; Aurora SK; Tockhorn-Heidenreich A; Lipton RB
Neurology; 2019 Jul; 93(5):e508-e517. PubMed ID: 31270220
[TBL] [Abstract][Full Text] [Related]
9. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
[TBL] [Abstract][Full Text] [Related]
10. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.
Lipton RB; Buse DC; Sandoe CH; Ford JH; Hand AL; Jedynak JP; Port MD; Detke HC
Headache; 2023 May; 63(5):683-691. PubMed ID: 36797223
[TBL] [Abstract][Full Text] [Related]
11. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
Zhou J; Zhong L; Chowdhury D; Skorobogatykh K; Luo G; Yang X; Zhang M; Sun L; Liu H; Qian C; Yu S
J Headache Pain; 2023 Aug; 24(1):103. PubMed ID: 37542222
[TBL] [Abstract][Full Text] [Related]
12. Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis.
Ailani J; Andrews JS; Tockhorn-Heidenreich A; Wenzel R; Rettiganti M
Adv Ther; 2022 Oct; 39(10):4544-4555. PubMed ID: 35930126
[TBL] [Abstract][Full Text] [Related]
13. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
Tepper SJ; Ailani J; Ford JH; Nichols RM; Li LQ; Kemmer P; Hand AL; Tockhorn-Heidenreich A
Clin Drug Investig; 2022 Mar; 42(3):263-275. PubMed ID: 35041159
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
Smitherman TA; Tietjen GE; Schuh K; Skljarevski V; Lipsius S; D'Souza DN; Pearlman EM
Headache; 2020 Nov; 60(10):2202-2219. PubMed ID: 33063862
[TBL] [Abstract][Full Text] [Related]
15. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
[TBL] [Abstract][Full Text] [Related]
16. Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study.
Takeshima T; Doi H; Ooba S; Tanji Y; Ozeki A; Komori M
Neurol Ther; 2024 Jun; 13(3):697-714. PubMed ID: 38581615
[TBL] [Abstract][Full Text] [Related]
17. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
18. Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study.
Shibata M; Nakamura T; Ozeki A; Ueda K; Nichols RM
J Pain Res; 2020; 13():3531-3538. PubMed ID: 33408512
[TBL] [Abstract][Full Text] [Related]
19. Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study.
Tatsuoka Y; Takeshima T; Ozeki A; Matsumura T
Neurol Ther; 2021 Jun; 10(1):265-278. PubMed ID: 33835383
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
